Compare COOK & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | PLRX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.7M | 81.1M |
| IPO Year | 2021 | 2020 |
| Metric | COOK | PLRX |
|---|---|---|
| Price | $33.66 | $1.30 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $53.00 | $2.67 |
| AVG Volume (30 Days) | 97.6K | ★ 485.4K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $559,520,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $1.09 |
| 52 Week High | $35.56 | $1.95 |
| Indicator | COOK | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.74 | 52.19 |
| Support Level | $0.92 | $1.12 |
| Resistance Level | $35.56 | $1.38 |
| Average True Range (ATR) | 2.54 | 0.07 |
| MACD | -0.39 | 0.00 |
| Stochastic Oscillator | 82.05 | 72.92 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.